Real-world adalimumab survival and discontinuation factors in hidradenitis suppurativa
Background and Objectives: Survival analyses can provide valuable insights into effectiveness and safety as perceived by prescribers. Here, we aimed to evaluate adalimumab (ADA) survival and the interruption risk factors in a multicentre cohort of patients with hidradenitis suppurativa (HS). Moreove...
| Autores: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | artículo |
| Fecha de publicación: | 2025 |
| País: | España |
| Recursos: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:ddd.uab.cat:321055 |
| Acesso em linha: | https://ddd.uab.cat/record/321055 https://dx.doi.org/urn:doi:10.1111/jdv.20044 |
| Access Level: | acceso abierto |
| Palavra-chave: | Adalimumab Survival Discontinuation Hidradenitis suppurativa |
| id |
ES_faee2ac4aab1ff237e73009a57c16b26 |
|---|---|
| oai_identifier_str |
oai:ddd.uab.cat:321055 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Real-world adalimumab survival and discontinuation factors in hidradenitis suppurativaGarbayo-Salmons, Patricia|||0000-0003-3325-6785Vilarrasa-Rull, Eva|||0000-0001-6507-0534Bassas-Vila, Julio|||0000-0003-2787-750XMora Fernández, Verónica|||0000-0003-0016-9781Fuertes, IreneLuque-Luna, Mar|||0000-0002-0981-9149Fornons-Servent, RosaMartin-Ezquerra, Gemma|||0000-0002-5106-7526Aguayo Ortiz, Rafael|||0000-0002-1690-1618Ceravalls, Joan|||0000-0003-0720-9280Mollet, JordiGómez Tomás, ÁlvaroMasferrer i Niubò, Emili|||0000-0002-0763-2815Corral-Magaña, OriolMatas-Nadal, Clara|||0000-0001-9911-6924del Estal, Jorge|||0000-0001-7299-2211Fuertes Bailón, DaniCalvet, Joan|||0000-0002-0888-5152Romaní, Jorge|||0000-0002-6134-5155AdalimumabSurvivalDiscontinuationHidradenitis suppurativaBackground and Objectives: Survival analyses can provide valuable insights into effectiveness and safety as perceived by prescribers. Here, we aimed to evaluate adalimumab (ADA) survival and the interruption risk factors in a multicentre cohort of patients with hidradenitis suppurativa (HS). Moreover, we performed a subanalysis considering the periods before and after the onset of the COVID-19 pandemic. Methods: We conducted a retrospective study including 539 adult patients with HS who received ADA from 1 May 2015 to 31 December 2022. Overall drug survival was analysed using Kaplan-Meier survival curves and compared between the subgroups via stratified log-rank test. Possible predictors for overall drug survival and reasons for discontinuation were assessed using univariate and multivariate Cox regression. Results: Overall, 50.1% were females with a mean age of 43.5 ± 1 years and a mean BMI of 29.5 ± 6.7. At the start of ADA, 95.29% were biologic-naïve and 24.63% had undergone surgical treatment. During follow-up, 9.46% of patients required dose escalation, while 39.92% interrupted ADA. Concomitant therapy was used in 64.89% of cases. A subanalyses comparing pre- and post-pandemic periods revealed a tendency to initiate ADA treatment at a younger age, among patient with higher BMI and at a lower HS stage after COVID-19 pandemic. Interestingly, ADA demonstrated extended survival compared to previous studies, with a median overall drug survival of 56.2 months (95% CI 51.2 to 80.3). The primary causes for discontinuation were inefficacy (51.69%), followed by adverse effects (21.35%). Female sex, longer delay in HS diagnosis, higher baseline IHS4 score and concomitant spondyloarthritis were associated with poorer ADA survival or increased risk of discontinuation. Conclusions: ADA demonstrated prolonged survival (median 56.2 months). While addition of antibiotics did not have a positive effect on survival rate, basal IHS4 proved useful in predicting ADA survival. 22025-01-0120252025-01-01Articlehttp://purl.org/coar/resource_type/c_6501AMhttp://purl.org/coar/version/c_ab4af688f83e57aainfo:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/321055https://dx.doi.org/urn:doi:10.1111/jdv.20044reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest material està protegit per drets d'autor i/o drets afins. Podeu utilitzar aquest material en funció del que permet la legislació de drets d'autor i drets afins d'aplicació al vostre cas. Per a d'altres usos heu d'obtenir permís del(s) titular(s) de drets.https://rightsstatements.org/vocab/InC/1.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3210552026-06-06T12:50:31Z |
| dc.title.none.fl_str_mv |
Real-world adalimumab survival and discontinuation factors in hidradenitis suppurativa |
| title |
Real-world adalimumab survival and discontinuation factors in hidradenitis suppurativa |
| spellingShingle |
Real-world adalimumab survival and discontinuation factors in hidradenitis suppurativa Garbayo-Salmons, Patricia|||0000-0003-3325-6785 Adalimumab Survival Discontinuation Hidradenitis suppurativa |
| title_short |
Real-world adalimumab survival and discontinuation factors in hidradenitis suppurativa |
| title_full |
Real-world adalimumab survival and discontinuation factors in hidradenitis suppurativa |
| title_fullStr |
Real-world adalimumab survival and discontinuation factors in hidradenitis suppurativa |
| title_full_unstemmed |
Real-world adalimumab survival and discontinuation factors in hidradenitis suppurativa |
| title_sort |
Real-world adalimumab survival and discontinuation factors in hidradenitis suppurativa |
| dc.creator.none.fl_str_mv |
Garbayo-Salmons, Patricia|||0000-0003-3325-6785 Vilarrasa-Rull, Eva|||0000-0001-6507-0534 Bassas-Vila, Julio|||0000-0003-2787-750X Mora Fernández, Verónica|||0000-0003-0016-9781 Fuertes, Irene Luque-Luna, Mar|||0000-0002-0981-9149 Fornons-Servent, Rosa Martin-Ezquerra, Gemma|||0000-0002-5106-7526 Aguayo Ortiz, Rafael|||0000-0002-1690-1618 Ceravalls, Joan|||0000-0003-0720-9280 Mollet, Jordi Gómez Tomás, Álvaro Masferrer i Niubò, Emili|||0000-0002-0763-2815 Corral-Magaña, Oriol Matas-Nadal, Clara|||0000-0001-9911-6924 del Estal, Jorge|||0000-0001-7299-2211 Fuertes Bailón, Dani Calvet, Joan|||0000-0002-0888-5152 Romaní, Jorge|||0000-0002-6134-5155 |
| author |
Garbayo-Salmons, Patricia|||0000-0003-3325-6785 |
| author_facet |
Garbayo-Salmons, Patricia|||0000-0003-3325-6785 Vilarrasa-Rull, Eva|||0000-0001-6507-0534 Bassas-Vila, Julio|||0000-0003-2787-750X Mora Fernández, Verónica|||0000-0003-0016-9781 Fuertes, Irene Luque-Luna, Mar|||0000-0002-0981-9149 Fornons-Servent, Rosa Martin-Ezquerra, Gemma|||0000-0002-5106-7526 Aguayo Ortiz, Rafael|||0000-0002-1690-1618 Ceravalls, Joan|||0000-0003-0720-9280 Mollet, Jordi Gómez Tomás, Álvaro Masferrer i Niubò, Emili|||0000-0002-0763-2815 Corral-Magaña, Oriol Matas-Nadal, Clara|||0000-0001-9911-6924 del Estal, Jorge|||0000-0001-7299-2211 Fuertes Bailón, Dani Calvet, Joan|||0000-0002-0888-5152 Romaní, Jorge|||0000-0002-6134-5155 |
| author_role |
author |
| author2 |
Vilarrasa-Rull, Eva|||0000-0001-6507-0534 Bassas-Vila, Julio|||0000-0003-2787-750X Mora Fernández, Verónica|||0000-0003-0016-9781 Fuertes, Irene Luque-Luna, Mar|||0000-0002-0981-9149 Fornons-Servent, Rosa Martin-Ezquerra, Gemma|||0000-0002-5106-7526 Aguayo Ortiz, Rafael|||0000-0002-1690-1618 Ceravalls, Joan|||0000-0003-0720-9280 Mollet, Jordi Gómez Tomás, Álvaro Masferrer i Niubò, Emili|||0000-0002-0763-2815 Corral-Magaña, Oriol Matas-Nadal, Clara|||0000-0001-9911-6924 del Estal, Jorge|||0000-0001-7299-2211 Fuertes Bailón, Dani Calvet, Joan|||0000-0002-0888-5152 Romaní, Jorge|||0000-0002-6134-5155 |
| author2_role |
author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Adalimumab Survival Discontinuation Hidradenitis suppurativa |
| topic |
Adalimumab Survival Discontinuation Hidradenitis suppurativa |
| description |
Background and Objectives: Survival analyses can provide valuable insights into effectiveness and safety as perceived by prescribers. Here, we aimed to evaluate adalimumab (ADA) survival and the interruption risk factors in a multicentre cohort of patients with hidradenitis suppurativa (HS). Moreover, we performed a subanalysis considering the periods before and after the onset of the COVID-19 pandemic. Methods: We conducted a retrospective study including 539 adult patients with HS who received ADA from 1 May 2015 to 31 December 2022. Overall drug survival was analysed using Kaplan-Meier survival curves and compared between the subgroups via stratified log-rank test. Possible predictors for overall drug survival and reasons for discontinuation were assessed using univariate and multivariate Cox regression. Results: Overall, 50.1% were females with a mean age of 43.5 ± 1 years and a mean BMI of 29.5 ± 6.7. At the start of ADA, 95.29% were biologic-naïve and 24.63% had undergone surgical treatment. During follow-up, 9.46% of patients required dose escalation, while 39.92% interrupted ADA. Concomitant therapy was used in 64.89% of cases. A subanalyses comparing pre- and post-pandemic periods revealed a tendency to initiate ADA treatment at a younger age, among patient with higher BMI and at a lower HS stage after COVID-19 pandemic. Interestingly, ADA demonstrated extended survival compared to previous studies, with a median overall drug survival of 56.2 months (95% CI 51.2 to 80.3). The primary causes for discontinuation were inefficacy (51.69%), followed by adverse effects (21.35%). Female sex, longer delay in HS diagnosis, higher baseline IHS4 score and concomitant spondyloarthritis were associated with poorer ADA survival or increased risk of discontinuation. Conclusions: ADA demonstrated prolonged survival (median 56.2 months). While addition of antibiotics did not have a positive effect on survival rate, basal IHS4 proved useful in predicting ADA survival. |
| publishDate |
2025 |
| dc.date.none.fl_str_mv |
2 2025-01-01 2025 2025-01-01 |
| dc.type.none.fl_str_mv |
Article http://purl.org/coar/resource_type/c_6501 AM http://purl.org/coar/version/c_ab4af688f83e57aa |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://ddd.uab.cat/record/321055 https://dx.doi.org/urn:doi:10.1111/jdv.20044 |
| url |
https://ddd.uab.cat/record/321055 https://dx.doi.org/urn:doi:10.1111/jdv.20044 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://rightsstatements.org/vocab/InC/1.0/ |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://rightsstatements.org/vocab/InC/1.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.source.none.fl_str_mv |
reponame:Dipòsit Digital de Documents de la UAB instname:Universitat Autònoma de Barcelona |
| instname_str |
Universitat Autònoma de Barcelona |
| reponame_str |
Dipòsit Digital de Documents de la UAB |
| collection |
Dipòsit Digital de Documents de la UAB |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869425283023503360 |
| score |
15.812429 |